Amplia is pleased to share that our Head of Translational Biology, Dr Terrie-Anne Cock, will be presenting a poster on Thursday 9th February at the 35th Annual Lorne Cancer Conference.
Titled “A novel Focal Adhesion Kinase inhibitor AMP945 for first-line treatment of pancreatic cancer”, Terrie-Anne will outline the preclinical and clinical evidence gathered so-far that supports progression of AMP945 combination therapy in patients with advanced pancreatic cancer.
In addition, Dr Kendelle Murphy of the Garvan Institute of Medical Research will be presenting some of her most recent preclinical FAK research, including work undertaken with Amplia’s AMP945 in pancreatic cancer.
Read today’s ASX release
